SCHEMBL23717795

SCHEMBL23717795

CCCCCCC(CCCCC)C[C@H]1CCCN1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRCP P42785 3/20 0.42
CYP2D6 P10635 2/20 0.40
LMNA P02545 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
MLNR O43193 1/20 0.40
ABCB11 O95342 1/20 0.40
EGFR P00533 1/20 0.40
FYN P06241 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
HTR1A P08908 1/20 0.40
CHRM5 P08912 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22857521 1.00 PRCP (0.42) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL21964922 1.00 PRCP (0.42) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL22400200 1.00 PRCP (0.42) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL26895001 1.00 PRCP (0.42) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL24355611 1.00 PRCP (0.42) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL22871235 1.00 PRCP (0.42) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL22193313 0.98 PRCP (0.41) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL22193290 0.98 PRCP (0.41) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL24355747 0.95 SLC6A2 (0.46) PRCPCYP2D6LMNASLC6A2SLC6A4
SCHEMBL20780613 0.95 SLC6A2 (0.46) PRCPCYP2D6LMNASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R PRCP 480/4885CYP2D6 1931/4885LMNA 4172/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R PRCP 480/4885CYP2D6 1931/4885LMNA 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.